[{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Synspira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"SNSP003","moa":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cystic Fibrosis Foundation \/ Synspira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cystic Fibrosis Foundation \/ Synspira Therapeutics"},{"orgOrder":0,"company":"Allakos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lirentelimab","moa":"Siglec-8","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Allakos \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Allakos \/ Not Applicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Foralumab","moa":"T Cell surface glycoprotein CD3","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tiziana Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0.059999999999999998,"dosageForm":"Oral","sponsorNew":"Tiziana Life Sciences \/ ThinkEquity","highestDevelopmentStatusID":"1","companyTruncated":"Tiziana Life Sciences \/ ThinkEquity"},{"orgOrder":0,"company":"Avexegen Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"Neuregulin-4-based therapy","moa":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Avexegen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avexegen Therapeutics \/ NIH","highestDevelopmentStatusID":"1","companyTruncated":"Avexegen Therapeutics \/ NIH"},{"orgOrder":0,"company":"Tauriga Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Kratom Extract","moa":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tauriga Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Chewing Gum","sponsorNew":"Tauriga Sciences \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Tauriga Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alvogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rifaximin","moa":"RNA polymerase","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Alvogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alvogen \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Alvogen \/ Not Applicable"},{"orgOrder":0,"company":"NuLiv Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"AstraGin","moa":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"NuLiv Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NuLiv Science \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"NuLiv Science \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Capeserod","moa":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ First Wave BioPharma","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ First Wave BioPharma"},{"orgOrder":0,"company":"Infinant Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"INF108","moa":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Infinant Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Infinant Health \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Infinant Health \/ Not Applicable"}]

Find Novel Gastroenterology Drugs in Clinical Development

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pp

Contact Supplier

Check COS database
Check USDMF database

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

Pharma, Lab & Chemical Expo

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Capeserod

Therapeutic Area : Gastroenterology

Study Phase : Undisclosed

Sponsor : First Wave BioPharma

Deal Size : Undisclosed

Deal Type : Licensing Agreement

First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi

Details : Under the terms of the agreement, First Wave will receive from Sanofi an exclusive, global license for Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop for gastrointestinal (GI) indications.

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Undisclosed

September 14, 2023

Lead Product(s) : Capeserod

Therapeutic Area : Gastroenterology

Highest Development Status : Undisclosed

Sponsor : First Wave BioPharma

Deal Size : Undisclosed

Deal Type : Licensing Agreement

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Tilray

Canada

Pharma, Lab & Chemical Expo

Not Confirmed

03

Infinant Health

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

04

NuLiv Science

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

05

Alvogen

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

06

Tauriga Sciences

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

07

Jaguar Health

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

08

Hoth Therapeutics

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

09

Avexegen Therapeutics

U.S.A

Pharma, Lab & Chemical Expo

Not Confirmed

10

Tiziana Life Sciences

United Kingdom

Pharma, Lab & Chemical Expo

Not Confirmed

1
2